Filtered By:
Specialty: Hematology
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 2753 results found since Jan 2013.
D-dimer and the risk of hypertension: The REasons for Geographic And Racial Differences in Stroke Cohort Study
CONCLUSION: D-dimer concentration reflects pathophysiology related to the development of hypertension. Specific mechanisms require further study and may involve adiposity.PMID:36760775 | PMC:PMC9903654 | DOI:10.1016/j.rpth.2022.100016
Source: Thrombosis and Haemostasis - February 10, 2023 Category: Hematology Authors: Debora Kamin Mukaz Boyi Guo D Leann Long Suzanne E Judd Timothy B Plante Leslie A McClure Alisa S Wolberg Neil A Zakai George Howard Mary Cushman Source Type: research
Macrocytosis in Mitochondrial DNA Deletion Syndromes
Large single mtDNA (mitochondrial DNA) deletion syndrome is a rare inborn error of metabolism with variable heteroplasmy levels and clinical phenotype among affected individuals. Chronic progressive external ophthalmoplegia (CPEO) is the most common phenotype in adults with this form of mitochondrial disease [1-2]. The common CPEO clinical manifestations are ptosis and ophthalmoplegia. More variable phenotypic manifestations of CPEO (CPEO plus) include involvement of the peripheral nervous system and myopathy. Here, we describe a 62-year-old female with CPEO and the major mitochondrial DNA deletion present at 40% heteropla...
Source: Acta Haematologica - February 10, 2023 Category: Hematology Source Type: research
Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of thrombosis and/or pregnancy morbidity related to the presence of persistent antiphospholipid autoantibodies (aPL) [1]. The most frequent clinical manifestations of APS are thrombotic events and death may be caused by stroke, myocardial infarction, pulmonary embolism or catastrophic APS [2]. APS treatment is based on long term anticoagulation [3].
Source: Thrombosis Research - February 9, 2023 Category: Hematology Authors: Thomas Ballul, Arthur Mageau, Pascale Roland Nicaise, Nadine Ajzenberg, Andrey Strukov, Antoine Dossier, Diane Rouzaud, Thomas Papo, Karim Sacr é Tags: Letter to the Editors-in-Chief Source Type: research
Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke
Conclusion: Reversal of dabigatran with idarucizumab in stroke patients appears easy to manage, safe and beneficial. The SOPs aim to reassure stroke physicians to include dabigatran reversal into their daily clinical routine when dealing with patients presenting with ischemic or hemorrhagic stroke under dabigatran therapy.
Source: Journal of Thrombosis and Thrombolysis - February 4, 2023 Category: Hematology Source Type: research
Pitavastatin Compared with Differential Intervention Trial by Standard Therapy on Cardiovascular Events in Patients with Dyslipidemia on Chronic Hemodialysis (DIALYSIS): A Randomized Controlled Trial
Conclusion: Our study has demonstrated that aggressive intervention with pitavastatin is more effective than the standard (dietary) therapy for improving the clinical outcomes in patients with dyslipidemia on chronic hemodialysis.Blood Purif
Source: Blood Purification - January 30, 2023 Category: Hematology Source Type: research
Dilemmas in hematology: consults in patients with arterial thrombosis
J Thromb Haemost. 2023 Jan 10:S1538-7836(23)00030-2. doi: 10.1016/j.jtha.2023.01.002. Online ahead of print.ABSTRACTArterial thrombotic events, particularly ischemic stroke and myocardial infarction, are common, and mostly occur due to atherosclerotic disease or arrhythmias. The diagnosis and management of the majority of such events occurs without the involvement of a hematologist, following established guidelines or pathways. In this review, we discuss 3 scenarios in which optimal management is less certain. These scenarios concern patients with a left ventricular thrombus, in whom the duration and choice of anticoagulan...
Source: Thrombosis and Haemostasis - January 25, 2023 Category: Hematology Authors: Dawn Swan Jean M Connors Jecko Thachil Source Type: research
Letter to the Editor Re “Endovascular thrombectomy or bridging therapy in minor ischemic stroke with large vessel occlusion”
We commend Tu et al. on the recent article on comparison of endovascular thrombectomy (EVT) versus bridging therapy (BT) in minor stroke patients with large vessel occlusion (LVO) [1]. Based on retrospective, observational study of 903 patients, the authors conclude non-inferiority of EVT compared to BT in patients presenting within 4.5 h of onset. We have a few questions and comments.
Source: Thrombosis Research - January 24, 2023 Category: Hematology Authors: Ajay Malhotra, Mihir Khunte, Xiao Wu, Mahla Radmard Tags: Letter to the Editors-in-Chief Source Type: research
Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study
AbstractSleep disordered breathing (SDB) is a common underdiagnosed sequela of sickle cell disease (SCD) that has been linked to the frequency of vaso-occlusive crises. To determine the frequency of SDB in children with SCD and its association to SCD-related complications, thirty children and adolescents with SCD at their steady state underwent clinical, laboratory, and radiological assessment using transcranial duplex (TCD) and echo assessment of tricuspid regurge velocity (TRV). All participants had an overnight polysomnography after completing the modified STOP-Bang questionnaire. The mean age of the studied cohort was ...
Source: Annals of Hematology - January 16, 2023 Category: Hematology Source Type: research
A response to a letter to the editor TR-D-22-00887
In this study, we found that among patients with minor acute ischemic stroke due to large vessel occlusions (AIS-LVO), direct endovascular thrombectomy (EVT), compared with bridging therapy, met the prespecified statistical threshold for noninferiority for the 3-month prognosis [1].
Source: Thrombosis Research - January 16, 2023 Category: Hematology Authors: Wen-Jun Tu, Yicheng Xu Tags: Letter to the Editors-in-Chief Source Type: research
Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure
CONCLUSION: AMI patients have greater inflammation during the early and late phases than non-AMI patients. Risk phenotype of hsCRPbaseline correlates with 1-month outcomes only in AMI patients. Whereas the prognostic implication of this risk phenotype appears similar during the late phase, irrespective of the disease acuity.PMID:36634702 | DOI:10.1055/a-2011-8426
Source: Thrombosis and Haemostasis - January 12, 2023 Category: Hematology Authors: Haegeun Song Jong-Hwa Ahn Min Gyu Kang Kye Hwan Kim Jae Seok Bae Sang-Yeong Cho Jin Sin Koh Yongwhi Park Seok-Jae Hwang Eun Jeong Cho Kyeongmin Byeon Sang-Wook Kim Udaya S Tantry Paul A Gurbel Jin-Yong Hwang Young-Hoon Jeong Source Type: research
